Weigao Orthopaedics Reports 81% Net Profit Decline in 2023 Amidst National Volume-Based Procurement; Hansoh Pharma Posts 7.7% Revenue Growth Driven by Innovation
WEGO ORTHO
Orthopedic Medical Device Manufacturer
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
Fosun Pharmaceutical
Healthcare Industry Group
Kelun-Biotech
Innovative Drug Developer
Nuvation Bio
Tumor Drug Developer
The Aftermath of the Orthopedic Device Centralized Procurement Continues.
On March 26, WEGO ORTHO disclosed its 2023 annual report. During the reporting period, the company's revenue was 1.283 billion yuan, a year-on-year decrease of 37.62%; the net profit after deducting non-recurring items was 189 million yuan, a year-on-year decline of 81.68%.
Traditional pharmaceutical companies defend their glory.
Hansoh Pharma's 2023 annual report disclosed today shows that the company's operating revenue was RMB 10.104 billion, a year-on-year increase of 7.7%. The income from innovative drugs was RMB 6.865 billion, accounting for 67.9% of the revenue. The net profit attributable to shareholders of the listed company was RMB 3.278 billion, a year-on-year increase of 26.9%.
Another Chinese biotech sells out.
On March 25, Nuvation Bio announced that it would acquire AnHeart Therapeutics in an all-stock transaction.
In the past day, what are the hot topics worth paying attention to in the pharmaceutical markets at home and abroad? Let Amino take you through them.
/ 01 /
Market Express
1) A controlling subsidiary of Sinopharm Modern passes the Australian TGA-GMP certification
On March 26, Sinopharm Modern announced that recently, its controlling subsidiary Sinopharm Zhijun received the GMP certificate issued by the Australian Therapeutic Goods Administration (TGA). The company's Powder Injection Workshop Line 2 and Line 3 passed the TGA-GMP compliance inspection.
2) Jiangsu Ruike Biotech Co., Ltd. and SHANGHAI RONGSHENG BIOTECH CO.,LTD Sign Strategic Cooperation Agreement on Novel Adjuvant Vaccine Project
On March 25, Jiangsu Ruike Biotech Co., Ltd. and SHANGHAI RONGSHENG BIOTECH CO.,LTD successfully held the signing and project launch meeting for the novel adjuvant vaccine research and development project in Shanghai. At the meeting, both parties signed a strategic cooperation agreement on the novel adjuvant vaccine project and discussed the details of project advancement in depth.
/ 02 /
Capital Information
1) Tibet Rhodiola Pharmaceutical Holding Company's net profit increased by 116.56% year-on-year in 2023
On March 26, Tibet Rhodiola Pharmaceutical Holding Company released its 2023 annual report. During the reporting period, the company's operating revenue was 3.134 billion yuan, an increase of 22.69% year-on-year; net profit was 801 million yuan, an increase of 116.56% year-on-year.
2) WEGO ORTHO's Net Profit Declined by 81% Year-on-Year in 2023
On March 26, WEGO ORTHO disclosed its 2023 annual report. During the reporting period, the company's operating revenue was 1.283 billion yuan, a year-on-year decrease of 37.62%; the net profit after deducting non-recurring items was 189 million yuan, a year-on-year decline of 81.68%.
3) Hansoh Pharma's revenue increased by 7.7% year-on-year in 2023
On March 26, Hansoh Pharma disclosed its 2023 annual report. During the reporting period, the company's operating income was RMB 10.104 billion, an increase of 7.7% year-on-year. Revenue from innovative drugs amounted to RMB 6.865 billion, accounting for 67.9% of total revenue. Net profit attributable to shareholders of the listed company was RMB 3.278 billion, a year-on-year increase of 26.9%.
4) Fosun Pharmaceutical's revenue in 2023 was 41.4 billion yuan
On March 26, Fosun Pharmaceutical released its 2023 annual report. During the reporting period, the company's revenue was 41.4 billion yuan, with a year-on-year increase of approximately 12.43% excluding revenue from COVID-19 related products.
5) Kelun-Biotech's revenue in 2023 was 1.54 billion yuan
On March 25, Kelun-Biotech disclosed its 2023 annual report. During the reporting period, the company's revenue was 1.54 billion yuan, representing a year-on-year increase of 91.6%; R&D expenditure was 1.03 billion yuan, marking a year-on-year increase of 21.9%.
6) Boan Biotech Revenue in 2023 Reached 618 Million Yuan
On March 25, Boan Biotech disclosed its 2023 annual report. During the reporting period, the company's revenue was 618 million yuan, representing a year-on-year increase of 19.8%; the loss amounted to 119 million yuan.
7) I-Mab Biopharma Reports a Net Loss of 281 Million Yuan in 2023
On March 25, Yiming Angke disclosed its 2023 annual report. During the reporting period, the company's loss amounted to 281 million yuan, with an increased loss of 56 million yuan.
8) Bioheart reported a loss of 188 million yuan in 2023
On March 25, Bioheart disclosed its 2023 annual report. During the reporting period, the company's loss amounted to 188 million yuan, representing a year-on-year reduction in losses of 18.2%. As of the end of 2023, the company had cash and cash equivalents totaling 369 million yuan.
9) Laekna Therapeutics reported a loss of 458 million yuan in 2023
On March 25, Laikang Medicine disclosed its 2023 annual report. During the reporting period, the company's loss amounted to 458 million yuan, with cash and cash equivalents on the company's books totaling 440 million yuan.
10) CARsgen Therapeutics reported a loss of 733 million yuan in 2023
On March 26, CARsgen Therapeutics disclosed its 2023 annual report. During the reporting period, the company's loss amounted to 733 million yuan, with cash and cash equivalents on the company’s books totaling 1.849 billion yuan.
/ 03 /
Pharma Device Dynamics
1) Wuzhou Medical's medical device products receive FDA approval in the United States
On March 26, Wuzhou Medical announced that the company received a notice from the U.S. FDA on March 19, stating that its medical device product, HWJECT Auto-disable syringe (quantitative self-destructing syringe), has been approved for registration by the U.S. FDA.
2) CSPC's Semaglutide Injection Approved for Clinical Trials
On March 26, according to the CDE website, CSPC Pharmaceutical Group's Semaglutide Injection has been approved for clinical trials. It is intended for weight management in adult patients who are overweight or obese, based on reduced calorie intake and increased physical activity.
3) Roche's PI3Kα inhibitor proposed for inclusion in breakthrough therapy category
On March 25, according to the CDE official website, Roche's PI3Kα inhibitor GDC-0077 is proposed to be included in the breakthrough therapy category. The indication is: in combination with palbociclib and endocrine therapy for the treatment of adult patients with locally advanced or metastatic breast cancer who have PIK3CA mutations, are hormone receptor-positive, and human epidermal growth factor receptor 2-negative.
/ 04 /
Overseas Pharma News
1) AnHeart Therapeutics Acquired by Nuvation Bio
On March 25, Nuvation Bio announced that it would acquire AnHeart Therapeutics in an all-stock transaction.
2) Successful Phase III Study of Reboxetine in the Treatment of Narcolepsy
On March 25, Axsome announced that the Phase III SYMPHONY study of AXS-12 (reboxetine) for the treatment of narcolepsy met its primary endpoint, showing that AXS-12 significantly reduced the frequency of cataplexy in patients with narcolepsy.
Text by Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
